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1. Introduction 
1.1 Tuberculosis 
Tuberculosis is mainly an infectious disease of the lung (1, 2). Pulmonary tuberculosis 
continues to devastate the lives of millions of people worldwide, despite the availability of 
potent antibiotics against the causative pathogen Mycobacterium tuberculosis (3, 4). Eight to 
ten million new cases of clinical M. tuberculosis infection are diagnosed yearly, and the death 
toll due to tuberculosis has remained above 1.7 million people annually over the last two 
decades. The vast majority of M. tuberculosis infections occur in immuno-competent 
individuals (4, 5). Populations in Southeast Asia and sub-Saharan Africa are particularly 
vulnerable to the disease (3, 6). HIV co-infection and the recent emergence of drug resistant 
strains of M. tuberculosis have contributed to the escalation of tuberculosis in recent years (4, 
7-9). M. tuberculosis infection exhibits a complex life cycle driving the development of 
primary, latent, and post-primary tuberculosis in the human host (2, 5, 10-12). 
Primary tuberculosis is a granulomatous immune process that effectively contains M. 
tuberculosis within a few weeks after initial infection (1, 10, 13-15). Primary infection begins 
when previously uninfected individuals inhale aerosol droplets containing a few M. 
tuberculosis organisms that invade alveolar macrophages, epithelial cells, and dendritic cells 
in the distal airway mucosa. Mycobacteria arrest phagolysosome fusion and proliferate 
intracellularly in alveolar macrophages (16). The fate of mycobacteria in lung epithelial cells 
is not understood, but these cells are thought to participate in granuloma formation (17, 18), 
mycobacterial dissemination (19) and local antigen presentation to T lymphocytes (20). 
Infected dendritic cells migrate to regional lymph nodes resulting in activation and 
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migration of Th1 T lymphocytes back to the lung halting mycobacterial proliferation 
through intercellular contact with infected alveolar macrophages (21, 22). Dissemination of 
live mycobacteria or transport of mycobacterial antigens to peripheral immune organs by 
macrophages and dendritic cells establishes potent anti-mycobacterial immunity at the 
periphery (23-26). Elaboration of key cytokines such as TNF, IL-12, and IFN and 
chemokines drive formation of granulomas at sites of infection (27). Granulomas evolve into 
caseating lesions containing mycobacteria within a central core of lipid and activated foamy 
macrophages enclosed by layers of epithelioid cells and lymphocytes. Foamy macrophages 
undergo necrosis and calcification killing most M. tuberculosis organisms. The source of lipid 
causing foam cell formation is not established but may involve uptake of alveolar type II 
epithelial cell-derived surfactant lipids or adjoining adipose tissue (17). Healing of caseous 
lesions represents resolution of the primary infection which occurs asymptomatically in 
most immuno-competent individuals (2, 28).  
M. tuberculosis is not completely eradicated by primary cell-mediated immunity causing latent 
tuberculosis infection (LTBI) (10-12, 29). LTBI is thought to result from mycobacterial 
adaptation to the hypoxic lipid environment of caseous granulomas (14, 30, 31). A small 
number of bacteria survive presumably in macrophage phago-lysosomes in a non-replicative 
or dormant state. Cell-mediated immunity established during primary infection exerts life-
long control of LTBI in the host. Immunosuppressive therapy aimed at treating inflammatory 
and autoimmune diseases by targeting TNF, a crucial host factor in control of LTBI, results in 
reactivation of tuberculosis in latently infected individuals (29). LTBI is diagnosed using the 
purified protein derivative (PPD) skin test or interferon gamma release assays that measure 
mycobacterial antigen-specific recall responses of cell-mediated immunity. LTBI is present in 
over 3 billion people worldwide. Recent imaging observations in humans and non-human 
primates indicate that LTBI represents active rather than dormant subclinical infection 
contained within heterogeneous granulomatous lesions in the same host (11).  
Reinfection or reactivation of LTBI results in development of post-primary also called 
secondary tuberculosis in the lungs of individuals that have already developed robust 
immunity to the primary infection (2, 5). For reasons that are not understood, over-activation 
or perhaps unanticipated activation of the pulmonary immune system may steer the 
development of post-primary tuberculosis in the face of strong anti-tuberculosis immunity at 
the periphery. Individuals with LTBI have a 10% life-time risk of developing post-primary 
tuberculosis. Interestingly, post-primary tuberculosis occurs mainly in young adults aged 15-
40 years old (4, 5). Post-primary tuberculosis is responsible for 80% of clinical cases of 
tuberculosis and is the source of most transmission of the infection in the community. The 
more widely reported account of secondary tuberculosis pathology in the post-antibiotic era is 
that liquefaction of caseous granulomas results in formation of cavities. According to Hunter 
(5), however, post-primary tuberculosis manifests mainly as a lipid broncho-pneumonia, 
rather than a granulomatous disease process, that resolves spontaneously in most cases 
without further medical intervention. The view of post-primary tuberculosis as a lipid 
pneumonia agrees with the description of the disease reported by pathologists in the pre-
antibiotic era when tuberculosis was rampant in the Western World. Hunter’s observations are 
based on lung autopsies from patients who succumbed to tuberculosis but did not receive 
antibiotic therapy, reevaluation of specimen from the John Hopkins tuberculosis historical 
repository, and post-mortem lung biopsies of tuberculosis patients from Russia. Unresolved 
www.intechopen.com
 
Immunoregulatory Role of GM-CSF in Pulmonary Tuberculosis 
 
255 
post-primary tuberculosis lipid pneumonia progresses into caseous necrotic lesions in which 
mycobacteria reach high numbers. Caseous necrosis results in formation of cavities that release 
necrotic material along with large numbers of Mycobacterium tuberculosis organisms into main 
stem bronchi. Coughing then expels M. tuberculosis into the atmosphere completing the cycle 
of airborne transmission of the infection to other members of the community. Individuals with 
productive cavities but with minimal clinical symptoms can transmit the disease for many 
years before becoming seriously ill (5).  
Understanding geographical differences in immune responses to tuberculosis is essential for 
the rational design of effective vaccines against tuberculosis (4, 6, 32). Exposure to higher 
infection loads in countries where tuberculosis is endemic may contribute to immune 
exacerbations that increase the risk for development of active tuberculosis infection. 
Infection with helminths and environmental mycobacteria in developing countries is 
thought to cause immunological predisposition to active tuberculosis driven by a mixed 
Th1/Th2 cell-mediated immune response that also renders BCG vaccination ineffective (6, 
32-35). Helminth infections are prevalent in areas of the world were tuberculosis is also 
endemic. Helminths were shown to diminish the efficacy of the BCG vaccine. Co-infection 
of mice with the helminth Nippostrongylus brasiliensis and Mycobacterium tuberculosis 
increased mycobacterial burden in the lungs due to accumulation of alternatively activated 
macrophages. The effect of helminth infection was abrogated in mice lacking the IL-4 
receptor IL-4R indicating that IL-4 drives accumulation of alternatively activated 
macrophages with reduced capacity to control M. tuberculosis infection even in the presence 
of robust Th1 cell-mediated immunity (35).  
The role of GM-CSF in the broader context of vaccine development in the developing world 
where tuberculosis is an endemic disease is not yet understood. Monitoring of GM-CSF 
levels as a product of poly-functional T lymphocytes following BCG vaccination was 
adopted only recently (36). BCG vaccination of infants and children is effective but does not 
provide protection beyond adolescence and exhibits variable efficacy when administered in 
adults (37, 38). The failure of BCG vaccines to protect against tuberculosis in developing 
countries has confounded clinical and basic researchers for many years (38, 39). By contrast, 
BCG vaccination provides lasting protection in 80% of individuals in developed countries 
(33, 37). It is possible that primary infection is the predominant form of tuberculosis in 
developed countries where BCG vaccination works, whereas post-primary tuberculosis is 
the major form of infection in endemic countries were BCG vaccination does not work. GM-
CSF has been used in a variety of formulations and boosting strategies to enhance BCG 
priming of anti-tuberculosis cell-mediated immunity with promising results (40-45). So far, 
GM-CSF has been shown to enhance T cell responses and provide temporary benefit against 
primary infection with M. tuberculosis in pre-clinical models (41).  
2. GM-CSF functions in the lung 
GM-CSF is crucial for pulmonary homeostasis as a modulator of alveolar macrophage 
differentiation (46, 47). GM-CSF signals through a bi-component receptor of  and c 
subunits mediating concentration-dependent functions of GM-CSF in macrophages and 
other cell types. Assembly of the GM-CSF receptor heterodimer into hexameric or 
dodecameric forms underlies pleiotropic effector functions of GM-CSF (48). Secreted 
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constitutively at low levels by alveolar type II epithelial cells, GM-CSF is required for 
terminal alveolar macrophage differentiation (47, 49). Disruption of GM-CSF in both 
humans and mice results in development of alveolar proteinosis, a disease characterized by 
excessive accumulation of surfactant proteins and lipids in the alveolar space (50, 51). In the 
absence of GM-CSF, alveolar macrophages are arrested at an immature state with reduced 
capacity to internalize and catabolize surfactant (47, 52, 53). Normally, alveolar 
macrophages contribute 20-50% of surfactant catabolic activity in alveoli (54). In addition to 
surfactant catabolism, GM-CSF regulates phagocytosis and innate immune responses in 
alveolar macrophages (47, 55). GM-CSF modulates expression of the transcription factors 
PU.1 and PPAR. Optimal levels of PU.1 as maintained by GM-CSF are crucial for 
differentiation and multiple immune functions of alveolar macrophages (46, 47, 55-57) while 
in addition to PU.1, expression of PPAR is necessary for the catabolism of surfactant lipids 
by alveolar macrophages (58-60).  
GM-CSF coordinates regulatory functions of alveolar macrophages that modulate activation 
of pulmonary mucosal immunity and protection of the distal airway epithelium from 
inflammatory stimuli (61-63). GM-CSF regulates, recruitment, activation, and expansion of 
alveolar macrophages, alveolar type II epithelial cells, and dendritic cells (47, 64-66). Under 
normal conditions alveolar macrophages maintain immune homeostasis by inhibiting 
activation of T lymphocytes by innocuous antigens. Anti-inflammatory mediators such 
TGF, IL-10, nitric oxide, and constituents of pulmonary surfactant, SP-A, SP-D, and lipids 
contribute to the suppressive activities of alveolar macrophages (67, 68). In particular, the 
SP-A receptor SP-R210 moderates proliferation of lymphocytes in peripheral blood 
mononuclear cells of PPD+ individuals (69). High levels of GM-CSF inhibit the ability of 
alveolar macrophages to suppress mucosal immunity (63), representing an important switch 
mechanism between steady-state conditions and activation of cell-mediated immunity in the 
lung. On the other hand, optimal alveolar macrophage differentiation as normally 
maintained by epithelial derived GM-CSF in the lung, is necessary for appropriate innate 
immune responsiveness of alveolar macrophages. For example, induction of TNFsecretion 
by alveolar macrophages in response to LPS results in paracrine stimulation of high levels of 
GM-CSF by alveolar type II epithelial cells. High levels of GM-CSF stimulate proliferation of 
alveolar type II epithelial cells protecting the integrity of the alveolar epithelial barrier 
during acute inflammation (70).  
3. GM-CSF in treatment of tuberculosis 
Pre-clinical studies in animal models have shown that GM-CSF enhances the effectiveness of 
current vaccines against Mycobacterium tuberculosis (42). Studies in GM-CSF-deficient (GM-/-) 
mice showed that GM-CSF is necessary for the development of cell-mediated immunity and 
formation of granulomas against primary M. tuberculosis infection in the lung (71, 72). Prior 
vaccination of mice with GM-CSF-secreting Bacillus Calmette Guerin (BCG) reduced 
pulmonary M. tuberculosis numbers up to 100-fold when administered locally (41, 42). The 
best protection was achieved when BCG-GM-CSF was delivered directly to the lung.  
Systemic administration of high levels of GM-CSF, however, reduced anti-tuberculosis 
immunity in mice (73). Furthermore, GM-CSF-deficient mice in which GM-CSF is constantly 
secreted at high levels by lung epithelial cells (SP-C-GM+/+) are resistant to the infection 
initially but do not sustain long-term protective immunity against tuberculosis (71, 72), 
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suggesting that high levels of GM-CSF impact cell-mediated immunity in the chronic phase of 
the disease. On the other hand, lack of GM-CSF in mice was detrimental for survival against 
virulent M. tuberculosis Rv (74) and Erdman strains (72). These findings indicate that GM-CSF 
expression impacts host resistance to tuberculosis at different stages of the infection.  
Remarkably, neither GM-CSF deficiency nor constitutive over-secretion of GM-CSF 
influence clearance of the vaccine strain M. bovis BCG (71). Similarly, clearance of BCG and 
BCG-GM-CSF expressing strains were not different in WT mice (41). In a related study, 
pulmonary clearance of Mycobacterium avium was similar between WT and GM-/- mice, 
despite decreased activation of macrophages in the absence of GM-CSF (75). Both absence or 
high levels of GM-CSF disrupted normal granuloma formation in GM-/- and SP-C-GM+/+ 
but did not impact clearance of pulmonary BCG infection (71). Furthermore, abnormal 
levels of  GM-CSF did not impair secretion of IL-12p40 in response to BCG infection in GM-
/- and SP-C-GM+/+ mice (71). IL-12p40 is secreted by dendritic cells and is crucial for Th1 
cell-mediated immunity against tuberculosis (27, 76, 77). To this extend, lack of GM-CSF did 
not alter the ability of BCG to induce IL-12p40 (71). BCG infection in the presence of high 
levels of GM-CSF, however,  generated an early IFN burst  in SP-C-GM+/+ mice compared 
to WT and GM-/- mice 9 days after infection (Figure 1), and remained at the same high levels 
over the course of the experiment. In contrast, IFN increased gradually in WT mice 
reaching similar levels as SP-C-GM+/+ mice by 29 days after BCG infection. IFN levels in 
GM-/- lungs also increased gradually but were significantly lower than both WT and SP-C-
GM+/+ mice. The kinetics of IFN secretion in WT mice (Figure 1) correlates with the 
development of granulomatous inflammation following BCG infection (71). These studies 
indicate that GM-CSF modifies the initial IFN response to BCG vaccination. 
 
Fig. 1. GM-CSF modulates IFN levels in response to M. bovis BCG infection.  
WT, GM-/-, and SP-C-GM+/+ mice were infected with 1.5 x 107 cfu of M. bovis BCG via the 
intranasal route. The concentration of IFN was measured by ELISA in lung homogenates at 
indicated times after infection. ***p<0.001 compared to WT, GM-/-; &&&p<0.001 compared to  
GM-/-; $$p<0.01 compared to GM-/-. Data shown are means±S.E.M. n=9 for WT, n=10 for 
GM-/-, and n=6 for SP-C-GM+/+ mice. 
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Differences in GM-CSF levels alter long-term immune responses to BCG vaccination. ELISA 
assays compared levels of inflammatory mediators in the lungs of GM-/- and SP-C-GM+/+ 
mice at 53 and 75 days after infection with BCG (Figure 2). Figure 2A shows that GM-/- and 
SP-C-GM+/+ mice maintained similar levels of IFN 53 and 75 days after infection with BCG. 
 
Fig. 2. High levels of GM-CSF promote Th2 polirization after  M. bovis BCG infection.  
WT, GM-/-, and SP-C-GM+/+ mice were infected with 1.5 x 107 cfu of M. bovis BCG via the 
intranasal route. The concentrations of IFN, TNF, Il-2, IL-4, IL-10, and MCP-1 were 
measured by ELISA in lung homogenates at 53 and 75 days after infection. ***p<0.001 
compared to GM-/-. Data shown are means±S.E.M. n=4 for all mice. 
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The levels of TNF, however, were significantly higher in the lungs of SP-C-GM+/+ mice 
compared to GM-/- mice 53 days after infection, consistent with increased macrophage 
activation in the GM-CSF over-secreting mice (Figure 2B). The level of TNFin SP-C-GM+/+ 
micehoweverdecreased 75 days after intranasal immunization with BCG and was similar 
to GM-/- mice (Figure 2B), indicating suppression of macrophage activation in SP-C-GM+/+ 
mice at the later time point. Correspondingly, the levels of IL-2 (Figure 2C), IL-4 (Figure 2D), 
and IL-10 (Figure 2E) increased significantly 75 days after BCG immunization of  
SP-C-GM+/+ mice, indicating proliferation of T lymphocytes secreting immunosuppressive 
cytokines. The increase in IL-4 secretion suggests that high levels of GM-CSF in the context 
of BCG immunization results in activation of Th2 cell-mediated immunity in the long term. 
Furthermore, Figure 2F shows significantly increased levels of MCP-1 53 days after 
immunization with BCG in SP-C-GM+/+ mice that remained elevated at 75 days. MCP-1 is 
considered an important biomarker predictive of active TB infection or increased risk for 
development of active tuberculosis (78-81). In this regard, the SP-C-GM+/+ mice display 
delayed morbidity compared to GM-/- mice following infection with virulent M. tuberculosis; 
all SP-C-GM+/+ mice were alive at 53 days but their survival decreased after 70 days (71, 72). 
These results indicate that GM-CSF modifies transitional immune responses to 
mycobacterial infections between primary and chronic phases of the disease. 
4. GM-CSF coordinates immunopathology with lung resistance to  
M. tuberculosis 
Why does GM-CSF influence susceptibility to pulmonary M. tuberculosis but not to other 
mycobacterial species?  Histological analysis, mycobacterial localization, and measurements 
of immune responses of M. tuberculosis infected lungs from WT, GM-/- and SP-C-GM+/+ mice 
provided important insights (71). The previous studies and the findings presented here 
show that the balance between GM-CSF levels and mycobacterial load underlie the 
complexity of pathological and host immune responses in tuberculosis. 
In WT and SP-C-GM+/+ mice, the earliest lung response to M. tuberculosis infection was the 
appearance of macrophage aggregates in the interstitial space underlying alveolar epithelial 
cells 7 days after infection. This early response did not occur in GM-/- mice whereas interstitial 
lesions were restored and larger in SP-C-GM+/+ mice. Parenchymal interstitial lesions in WT 
mice had evolved into multicellular structures of epithelioid macrophages interspersed with 
lymphocytic infiltrates 15 days after infection. The WT lung epithelioid lesions persisted over 
time in lung parenchyma along with the appearance of highly organized peribronchial and 
submucosal granulomas containing lymphocyte aggregates and foamy macrophages 15 days 
onward. Interestingly, formation of epithelioid inflammation in WT mice contrasts the 
histopathology observed after infection with BCG where only lymphocytic granulomas in 
peribronchial/submucosal areas were observed (71). Lymphocytic granulomas containing 
clusters of lymphocytes were small and sparse in BCG infected SP-C-GM+/+ lungs. The M. 
tuberculosis infected SP-C-GM+/+ however, formed large epithelioid lesions, similar to those 
observed in WT mice, 15 days after infection but these disintegrated into smaller interstitial 
lesions over large areas of the lung parenchyma at later time points. Peribronchial and 
submucosal lymphocytic infiltrates in SP-C-GM+/+ mice were smaller than in WT mice but 
contained foamy and epithelioid macrophages. In contrast, the histology of GM-/- lungs, in 
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which epithelioid inflammation did not occur at early time points, were characterized by 
expansion of foamy macrophages consolidating multiple alveoli into necrotic nodules 
enriched in surfactant lipoprotein 21-28 days after infection (17, 71). 
The dynamics of mycobacterial infection was visualized using the highly sensitive 
auramine-rhodamine stain shown on Figure 3. Interstitial lesions were the site of M. 
tuberculosis proliferation in WT mice and were observed at both 15 and 29 days after  
 
Fig. 3. Effect of GM-CSF on M. tuberculosis localization in the lungs.  
A) Localization of M. tuberculosis infection in lung. WT, GM-/-, and SP-C-GM+/+ mice were 
infected with 100 M. tuberculosis cfu via aerosol. M. tuberculosis organisms were identified in 
lung tissue section 15 and 29 days after infection using auramine-rhodamine. M. tuberculosis 
were visualized in distal lung interstitial lesions in both WT and SP-C-GM+/+ mice (white 
arrow), but were retained in alveolar macrophages and alveolar lumen (open black arrows) 
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in GM-/- mice bacilli 15 days after infection. M. tuberculosis were found in smaller but more 
widespread interstitial lesions in both WT (white arrows) and SP-C-GM+/+ (green arrows) 
mice. In contrast, M. tuberculosis proliferated in intra-alveolar lesions in GM-/- mice 29 days 
after infection (red arrows). Magnification x40.  B) Microscopic quantitation of M. 
tuberculosis infection in lung. Both WT and SP-C-GM+/+ mice form bacteriostatic lesions 
while GM-/- mice cannot restrict MTB growth on day 29. Data are means  S.E.M ***p<0.001 
in GM-/- vs. all groups.  
infection (Fig. 3A, white arrows). Free aggregated M. tuberculosis organisms were observed 
in the alveolar lumen upon the alveolar epithelium. Some interstitial lesions were devoid of 
mycobacteria while others contained only a few clusters (Fig. 3A, white arrow heads). 
Previous assessment of mature lymphocytic granulomas in peribronchial and submucosal 
areas of the lungs localized single organisms in foamy macrophages in WT and SP-C-GM+/+ 
mice (17). The mycobacterial burden remained stable between 15 and 29 days in both WT 
and SP-C-GM+/+ mice (Figure 3B), likely reflecting the balance between poor control in the 
parenchyma and effective arrest of M. tuberculosis in mucosal lesions. In contrast to WT and 
SP-C-GM+/+ mice, M. tuberculosis organisms infected alveolar macrophages and were seen 
on the luminal side of alveolar epithelium 15 days after infection (Fig. 3A, open black 
arrows), but not in the interstitium of GM-/- mice. The presence of M. tuberculosis organisms 
in parenchymal interstitium of WT and SP-C-GM+/+ nut not in GM-/- mice suggests a 
potential route of local dissemination of the organism between parenchymal and mucosal 
sites; there were no differences in dissemination of M. tuberculosis to the spleen between the 
different mouse groups (unpublished data). The parenchymal tropism of M. tuberculosis was 
not evident using the more common Ziehls-Nielsen acid fast stain (unpublished results) but 
was readily detectable using the auramine-rhodamine stain used on Figure 3. The GM-/- 
mice developed full-blown pulmonary tuberculosis characterized by over a log increase in 
mycobacterial burden compared to WT and SP-C-GM+/+ mice (Figure 3B) (71). Numerous 
mycobacteria were located in foamy macrophages in intra-alveolar lipid rich lesions 
undergoing necrosis (Fig. 3A, red arrows) (17). Necrotic lesions also formed in a fraction of 
BCG-infected GM-/- mice but these were also rich in neutrophils, were enclosed by healing 
granulation tissue, and were devoid of BCG organisms. Most GM-/- mice eliminated lung 
BCG infection without formation of granulomas (71). These results support the concept that 
primary M. tuberculosis infection generates a heterogeneous histological response of 
epithelioid and lymphocytic granulomas, reflecting the ability of M. tuberculosis to invade 
the distal lung interstitium at early stage.  
That GM-CSF regulates a critical juncture between early parenchymal inflammation and 
activation of cell-mediated immunity was evidenced by significant differences in IL-12p40 
between WT, GM-/-, and SP-C-GM+/+ mice on day 14 (Figure 4A). IL-12p40, produced by 
dendritic cells, is critical for activation of IFN-secreting T lymphocytes in the lung. IL-12p40 
increased significantly between 7 and 14 days in both WT and SP-C-GM+/+ mice but not in 
GM-/- mice. The levels of IL-12p40 were similar in all mice at later times indicating that, in 
GM-/- mice IL-12p40 secretion is delayed but not impaired. In GM-/- mice, IL-12p40 
increased in a time-dependent manner after day 14. IL-12p40 increased in a time-dependent 
manner in WT mice that seemed to equilibrate by day 29, but in SP-C-GM+/+ mice peak IL-
12p40 levels were observed on day 14. The concentration of IFN was significantly higher in 
SP-C-GM+/+ mice 7 days after infection compared to WT and GM-/- mice, but not different  
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Fig. 4. GM-CSF modulates secretion of IL-12p40 and IFN in M. tuberculosis infection. 
WT, GM-/-, and SP-C-GM+/+ mice were infected with 100 M. tuberculosis cfu via aerosol. 
Lung IL-12p40 (A) and IFN (B) were measured in lung homogenates by ELISA. IL-12p40 
and IFNwere attenuated in GM-/- mice on day 14.  Significant differences in IL-12p40 were 
found on day 7 and 21:  *p<0.01 GM-/- vs WT and SP-C-GM+/+ on day 14,  **p<0.02 SP-C-
GM+/+ vs WT and GM-/- on day 21. * p<0.001 SP-C-GM+/+- vs WT and GM-/- on day 7. Data 
are means  S.E.M. n=4-6 for all groups. 
between WT and GM-/- mice (Figure 4B). The level of IFN was lower in GM-/- mice 15 days 
after infection and significantly below the levels of WT and SP-C-GM+/+ mice at this stage of 
infection. Subsequently, IFN plateaued 22 days after infection in WT mice. The highest 
amount of IFN in GM-/- mice was measured 29 days after infection, indicating delayed 
activation of T lymphocytes consistent with the IL-12p40 results on Figure 4A. Induction of 
IFN in SP-C-GM+/+ mice occurred early but subsequently was found to be variable and at 
overall lower levels (Figure 4B). The effect of different GM-CSF levels in kinetics of lung 
CD4+ and CD8+ T lymphocytes following M. tuberculosis infection are shown on Figure 5. In 
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Fig. 5. GM-CSF regulates activation of T lymphocytes in the lung.  
WT, GM-/-, and SP-C-GM+/+ mice were infected with 100 M. tuberculosis cfu via aerosol. Lungs 
were enzymatically dispersed into cell suspensions at indicated times after infection and 
lymphocytes analyzed by flow cytometry. The content of CD4+ (A), CD8+ (B) T lymphocytes 
were obtained by gating. Activated CD4+ (C) and CD8+ (D) T lymphocytes were obtained by 
staining cells with CD44 antibodies.  Data are means  S.E.M. n=4 for all groups. 
WT mice, lung CD4+ T lymphocytes increased in a time-dependent manner reaching an 
apparent plateau 28 days after infection (Figure 5B). In contrast, Figure 5B shows abnormal 
CD4+ T lymphocyte kinetics in SP-C-GM+/+ lungs with early recruitment 7 days after M. 
tuberculosis infection that equilibrated at lower levels 7-29 days after infection. Compared to 
WT mice, the CD8+ T lymphocyte content did not change over time in SP-C-GM+/+ lungs 
(Figure 5B). Despite the early influx of CD4+ T lymphocytes in SP-C-GM+/+ lungs, activation 
of CD4+ T lymphocytes, as indicated by expression of CD44, was similar in WT and SP-C-
GM+/+ mice (Figure 5C). In contrast, expression of CD44 was activated in CD8+ T lymphocytes 
in WT but not in SP-C-GM+/+ mice (Figure 5D). Both CD4+ and CD8+ T lymphocytes were 
found in low numbers and did not express CD44 in lungs of GM-/- mice (Figure 5A-D). 
Peripheral activation of T lymphocytes occured in the absence of GM-CSF, as shown by similar 
activation of CD44 in CD4+ and CD8+ T lymphocyte populations after M. tuberculosis infection 
(Figure 6A-D). The content of activated CD8+,CD44+ T lymphocytes, however, was higher in 
WT mice 28 days after infection compared to both GM-/- and SP-C-GM+/+ mice, indicating that 
peripheral activation of CD8 T cells is not optimal in the absence of GM-CSF.  
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Fig. 6. Effect of lung GM-CSF in activation of T lymphocytes in the spleen. WT, GM-/-, and SP-
C-GM+/+ mice were infected with 100 M. tuberculosis cfu via aerosol. Lungs were mechanically 
dispersed into cell suspensions at indicated times after infection and lymphocytes analyzed by 
flow cytometry. The content of CD4+ (A) and CD8+ (B) T lymphocytes were obtained by 
gating. Activated CD4+ (C) and CD8+ (D) T lymphocytes were obtained by staining cells with 
CD44 antibodies.  Data are means  S.E.M. n=4 for all groups. 
Surprisingly, 10-fold reduction in M. tuberculosis infection from 100-200 cfu to 10-20 cfu 
delayed morbidity significantly from 30-40 days weeks to six months in both GM-/- mice 
and from 70-90 days to 12 months in SP-C-GM+/+ mice (17). Histological evaluation of GM-/- 
lungs 6 months after low dose M. tuberculosis infection revealed intra-bronchial obstruction 
with surfactant rich material and necrotic cellular debris indicating collapse of alveolar 
spaces into bronchial airways. Interestingly, peribronchial spaces of obstructed airways 
contained lymphocytic infiltrates, suggesting that cell-mediated immunity against M. 
tuberculosis is abnormal histologically but not impaired in the absence of GM-CSF. On the 
other hand, the low dose infection in SP-C-GM+/+ mice generated large lymphocytic 
granulomas similar to WT mice and expansion of foamy macrophages in surrounding 
A B
C D
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alveoli contrasting the results following high dose M. tuberculosis infection described above 
(17, 71). These findings indicate an important relationship between GM-CSF levels and M. 
tuberculosis infection dose modulating histological remodeling in pulmonary tuberculosis. 
5. Discussion 
Histological studies indicate that GM-CSF facilitates formation of early epithelioid granulomas 
in lung parenchyma during the innate phase of M. tuberculosis infection. GM-CSF expression is 
required for the development of interstitial granulomas as indicated by the absence of 
interstitial lesions in GM-/- mice and formation of enlarged epithelioid lesions in SP-C-GM+/+ 
mice in the first 15 days after M. tuberculosis infection. This early histological response involves 
recruitment of macrophages and other immune cells leading the differentiation of interstitial 
lesions enriched in epithelioid cells. Initial granuloma formation begins with alveolar 
deposition of M. tuberculosis organisms resulting in not only infection of alveolar macrophages 
but also trafficking and proliferation of M. tuberculosis in interstitial granulomas. In contrast to 
WT and SP-C-GM-CSF+/+ mice, alveolar macrophages were the main site of infection in GM-/- 
mice, indicating that GM-CSF is not required for infection of alveolar macrophages by M. 
tuberculosis, whereas GM-CSF is required for the early dissemination of M. tuberculosis into 
lung interstitium. Differences in GM-CSF levels, however, did not influence or alter distal 
dissemination to the spleen (unpublished data), indicating that peripheral and local 
dissemination of M. tuberculosis infection involve different mechanisms. Transport of infected 
macrophages or infection of epithelial cells may contribute to early interstitial dissemination of 
M. tuberculosis. GM-CSF-induced differentiation of alveolar macrophages or expression of 
mycobacterial receptors on alveolar epithelial cells may be required to relocate M. tuberculosis 
from the alveolar lumen to lung interstitium. Previous studies reported that M. tuberculosis 
uses the cell-surface hemagglutinin HBHA to trancytose across alveolar epithelial cells (82). 
More recently, it was shown that M. tuberculosis and its close relative M. marinum spread 
between cells via the ejectosome (83), an actin-based non-lytic mechanism that requires 
expression of the ESX-1 secretion system. The ESX-1 secretion system of M. tuberculosis 
mediates export of the highly immunogenic antigen ESAT-6. Mycobacterial organisms such as 
M. avium and M. bovis BCG that lack ESX-1 do not disseminate through ejectosomes. The early 
epithelioid granuloma drives activation of cell-mediated immunity as indicated by marked 
induction of IL-12p40 in WT and SP-C-GM+/+ mice but not in GM-/- mice two weeks after M. 
tuberculosis infection. It is possible that epithelioid macrophages are an intermediate source of 
M. tuberculosis antigen presentation that dendritic cells acquire en route to lymph nodes, a 
process that takes two weeks to complete before activation of protective immunity against M. 
tuberculosis. Formation of parenchymal epithelioid lesions leading to activation of IL-12p40 
secretion preceded the appearance of lymphocytic granulomas in mucosal and peri-bronchial 
sites establishing cell-mediated immunity and long-term control of the infection in the lung.  
GM-CSF suppresses formation of foamy alveolar macrophages in M. tuberculosis infected 
lungs. Macrophage-derived foam cells arise by accumulation of intracellular lipids. 
Macrophage-derived foam cells are a characteristic feature of primary and post-primary 
tuberculosis lesions in lungs of both mice and humans (84-86). Macrophage foam cells may 
facilitate resolution of infection with the vaccine strain M. tuberculosis BCG (87), but are 
thought to have pathogenic roles in M. tuberculosis infection. M. tuberculosis cell wall lipids 
contribute to foam cell formation by inducing accumulation of lipid bodies in macrophages 
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(84, 88). Foam cells may modify the ability of M. tuberculosis as a persistent or a resurgent 
pathogen during latent (89, 90) and post-primary tuberculosis (86), respectively. Lipid 
bodies that fuse with phago-lysosomes are thought to provide cholesterol and other host 
lipid nutrients facilitating persistence of M. tuberculosis (90-92). Foamy macrophages, in 
which M. tuberculosis organisms were identified at later stages of infection, were a 
distinguishing feature of lymphocytic granulomas in WT lungs and SP-C-GM+/+ mice. In the 
latter case, large lymphocytic granulomas with expansion of foamy alveolar macrophages 
was present after low but not high dose infection with M. tuberculosis. In contrast to WT and 
SP-C-GM+/+ mice, expansion of foamy macrophages evolving into necrotic granulomas 
filling alveolar and bronchial spaces was the only lesion that developed three weeks after 
infection of GM-/- mice with M. tuberculosis infection. Induction of IL-12p40 and IFN was 
not abrogated but occurred at late stages of infection apparently providing adequate 
immunity that prolonged survival at low dose infection with M. tuberculosis. Necrotic 
granulomas obstructing alveolar and bronchial spaces were enriched in pulmonary 
surfactant. Interestingly, staining surfactant proteins in normal mice indicated that 
surfactant lipoprotein is actively produced by alveolar type II epithelial within tuberculous 
granulomas (17). Given the essential and selective role of GM-CSF in degradation of 
surfactant lipids (46, 58), it is reasonable to speculate that foamy macrophages in 
tuberculosis represent macrophages that have lost the capacity to respond to GM-CSF 
forming a suitable environment for M. tuberculosis to maintain its life cycle in the long term. 
6. Hypothesis 
The model on Figure 7 depicts that differences in GM-CSF levels control the balance between 
protective and escape mechanisms through which M. tuberculosis is either controlled or causes 
infection transmitting infection to other individuals. The histological presentation of primary 
tuberculosis at early stage of infection is discerned by three morphologically distinct but 
interacting processes. GM-CSF is necessary for the development of epithelioid granulomas in 
lung parenchyma 0-15 days after infection, a period known as the innate phase of the infection. 
Epithelioid granulomas govern the development of cell-mediated immunity in the form of 
lymphocytic granulomas which curb proliferation of M. tuberculosis in the lung. Macrophages 
that lose the ability to respond to GM-CSF constitute the escape mechanism that transitions 
primary tuberculosis to chronic infection. Foamy macrophages accumulate lipids that may 
provide a permissive environment for mycobacteria to survive. Foamy macrophages remain in 
constant interaction with adaptive immune cells preventing mycobacterial proliferation in the 
long-term. High levels of GM-CSF generated at the chronic or latent stage of tuberculosis may 
alter polarization of the immune response resulting in reactivation of the infection in foamy 
macrophages. As a result, development of post-primary tuberculosis may progress to cavities 
transmitting the disease to other individuals through coughing. At this stage, depending on 
the cause of GM-CSF secretion, GM-CSF may work to the host’s benefit to resorb lipid through 
recruitment and differentiation of macrophages facilitating resolution of cavitary tuberculosis, 
as occurs in most individuals with post-primary tuberculosis (93), or promote disease 
development through inappropriate polarization of the immune response in the lung. At this 
point it should be noted that BCG immunization in the context of high levels of GM-CSF was 
associated with Th2 polarization after clearance of BCG (Figure 2). BCG has been highly 
effective against tuberculosis in children preventing dissemination of the disease that causes 
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tuberculous meningitis, but fails to prevent activation of the disease in adults. Millions of 
children receive BCG vaccination yearly. Differences in lung GM-CSF in endemic populations 
may contribute to the failure of the BCG vaccine once these individuals become adults and it is  
 
Fig. 7. Hypothesis on the role of GM-CSF in pathogenesis of pulmonary tuberculosis.GM-
CSF is required for initiation of protective immunity against primary tuberculosis by 
inducing optimal formation of epithelioid and lymphocytic granulomas. M. tuberculosis 
survives in foamy macrophages that do not respond to GM-CSF. Long-term adaptive 
immunity regulates transition to latent tuberculosis by suppressing mycobacterial 
proliferation in foamy macrophages. Excess production of GM-CSF during latent infection 
alters the balance of adaptive immunity resulting in reactivation of M. tuberculosis infection 
in foam cells. Reactivation of M. tuberculosis causes development of post-primary 
tuberculosis and formation of cavities that transmit tuberculosis disease. 
not unreasonable to suggest that it could contribute to post-primary tuberculosis, the most 
common form of the disease in the developing world. Given the hypothesis that latent M. 
tuberculosis infection hides in foamy macrophages under the incomplete surveillance of cell-
mediated immunity, the mouse models described here present unique opportunities to test 
vaccine strategies targeting the infection in its natural host cell.  
7. Methods 
7.1 Mice 
Specific pathogen-free male or female C57Bl/6 mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). The generation C57BL/6 GM-/- and SP-C-GM+/+/GM-/- mice 
was described previously (50, 94). Mice were housed and bred under specific-pathogen free 
conditions. Mice were transferred to a BSL-3 vivarium for experiments and were used at 
between 4-6 weeks of age in accordance with IACUC approved protocols.  
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7.2 Bacteria 
Mycobacterium tuberculosis (MTB) H37Rv (#27294) was from the ATCC repository. The M. 
bovis BCG strain Tokyo strain S-10 was a kind gift of Dr. Malini Rajagopalan, University of 
Texas Health Science Center at Tyler. Colonies (CFU) grown on 7H11 agar were sub-
cultured in 7H9 broth and log phase organisms were harvested 10-12 days later. Bacteria 
were washed in PBS and sonicated at 5 watts for 15 seconds to disperse organisms and 
stored in aliquots at –70oC in 70% glycerol-PBS. One thawed aliquot was diluted ten-fold in 
PBS and plated for CFU counts on 7H11 agar. 
7.3 Infections of mice 
Pulmonary infections with 1.5 x 107 BCG were established intranasaly as previously 
described. Aerosol infections were performed in a Middlebrook aerosol exposure chamber 
(Glascol Inc, Terre Haute, IN). A sonically dispersed suspension of MTB at 106 CFU/mL in 
saline was nebulized for 30 min, which implanted around 2.0 log10 CFU/mouse lung. All 
mouse groups were exposed to the MTB aerosol at the same time. Mice were sacrificed on 
indicated time points and lungs and spleens were aseptically removed. Organs were 
homogenized in PBS with 0.05% Tween-80 and ten-fold dilutions plated on 7H11 agar for 
enumeration of CFU counts.  
7.4 Localization of mycobacteria in lungs 
Infected organs were fixed in 10% formalin and embedded in paraffin. Mycobacteria were 
visualized using an auramine-rhodamine staining kit (BD Biosciences, San Diego, CA). 
Fluorescent images were captured using TE 100 inverted microscope equipped with a 
Cooke Sensicam digital camera (3I imaging Denver, Co). The MTB burden in infected 
lesions was estimated as fluorescent pixels/microscopic field from six randomly selected 
microscopic fields by using morphometry tools embedded in Slidebook software (3I 
imaging, Denver, Co). Tissues were interrogated at 40x magnification.  
7.5 ELISA 
Lung homogenates were filtered using 0.2  syringe filters prior to ELISA assays that 
measured the concentration of IFN, IL-12, IL-10, IL-4, MCP-1, and TNF. All kits were 
obtained from eBiosciences (San Diego, CA). 
7.6 Flow cytometry 
Single cell suspensions were obtained from lung and spleen. Lungs were perfused with cold 
sterile phosphate buffered saline (PBS), minced and digested in PBS containing  1 mM EDTA , 
100 U /mL collagenase, 50 µg/ml elastase and 1 µg/ml  DNAase (Sigma Alidrich, MO) for 45 
min at 37oC. The digest was then passed through a 0.45  nylon mesh to obtain single cell 
suspensions. The cells were centrifuged and then suspended and stained in FACS buffer (PBS, 
supplemented with 2% heat inactivated goat serum, 0.5% fetal calf serum, 10 g/ml Fc block 
and 0.02% azide). The T cells were stained with conjugated antibodies against the following 
antigens (BD PharMingen): CD3 (anti-CD3-PE, clone 145.2C11), CD4 (anti-CD4-FITC, clone 
H129.19), CD8 (anti-CD8-FITC, clone 53-6.7), and CD44 (anti-CD44-PE, clone IM7). Dual 
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staining of lymphocytes was accomplished using antibodies to CD4 or CD8 along with 
antibodies against CD44. Cells were fixed with 2% paraformaldehyde for 1 h and analyzed by 
flow cytometry using CellQuest software (BD Immunocytometry Systems, San Jose, CA). Cells 
were gated on the lymphocyte and monocytes by forward and side scatter.  
7.7 Statistics 
Graphing and statistical analysis was accomplished using Graphpad Prism 4.0 software 
(www.graphpad.com). Statistical comparisons were assessed by two-way ANOVA, and 
differences were considered significant at p<0.05.  
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